Our results uncovered that AS-IV can protect retinal cells against diabetes induced retinopathy, which may act on target proteins AKT1, CASP3 and HIF1α, VEGFA, IL6, IL1β, SRC and CTNNB1, and might be involved in the regulation of PI3K-AKT signaling pathway. Here, CTNNB1 is linked to retinal disorder.